Repaglid 1

Generic

Repaglinide

 

Indications

In patients with type 2 diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled adequately by diet and exercise alone, repaglinide is used as an addition to diet and exercise to lower blood glucose. It's also approved for use with Metformin to help individuals with hyperglycemia who can't control their blood sugar with exercise, diet, or either Repaglinide or Metformin alone.

 

Pharmacology

Repaglinide binds to specific receptors in the cell membrane, causing ATP-dependent K+ channels to close and the cell membrane to depolarize. This results in Ca++ inflow, increased intracellular Ca++, and insulin secretion stimulation.

 

Dosage & Administration

For patients not previously treated or whose HbA1c is <8%, the starting dose should be 0.5 mg before each meal.

For patients previously treated with blood glucose-lowering drugs and whose HbA1c is >8%, the initial dose is 1 or 2 mg before each meal.

Repaglinide should be taken immediately or up to 30 minutes before each meal.

Dosage should be adjusted according to response at intervals of 1-2 weeks; up to 4 mg may be given as a single dose, maximum 16 mg daily.

 

Interaction

If Repaglinide is taken with other drugs, the dose may need to be modified. Repaglinide may interact with the following medications:

• Repaglinide clearance and half-life may be affected by inhibitors of the cytochrome P450 enzyme system (azole antifungals and macrolides).
• Rifampin, Phenobarbital, Carbamazepine, Troglitazone, and other inducers of the cytochrome P450 enzyme system may speed up Repaglinide metabolism and abbreviate its action.
• Cimetidine has no effect on the absorption or elimination of Repaglinide.
• Digoxin, Theophyllin, and Warfarin are not affected by Repaglinide.
• Drugs that are highly protein bound (e.g., NSAIDs) may raise the plasma level of unbound Repaglinide, potentiating its glucose-lowering action.
• As a result, using these medicines together with Repaglinide may raise the risk of hypoglycemia.
• When hypoglycaemic agents are combined with other medications including salicylates, sulphonamides, chloramphenicol, coumarins, Probenecid, monoamine oxidase (MAO) inhibitors, and adrenergic blockers, the risk of hypoglycemia is enhanced.

 

Contraindications

Diabetic ketoacidosis, with or without coma, is contraindicated in individuals using repaglinide.

Diabetes mellitus type 1 and a history of hypersensitivity to the medication or its inactive components.

 

Side Effects

Hypoglycemia and associated symptoms are the most common Repaglinide adverse effects. Upper respiratory infections, diarrhea, constipation, nausea, and vomiting are among the other symptoms. Rashes and urticaria are examples of hypersensitivity reactions.

 

Pregnancy & Lactation

There is no evidence of safety in pregnant women. Repaglinide should only be taken during pregnancy if it is absolutely necessary. Repaglinide is not known to be excreted in human milk. Because many medications are excreted in human milk and because Repaglinide can cause major adverse reactions in nursing infants, a choice should be made whether to stop breastfeeding or stop taking the drug, taking into account the drug's importance to the mother.

 

Precautions & Warnings

Affront ought to be substituted amid concurrent sickness (such as myocardial dead tissue, coma, disease, and injury) and amid surgery. All verbal blood glucose-lowering drugs are competent of creating hypoglycemia. Repaglinide ought to be managed with suppers to reduce the chance of hypoglycemia.

 

Therapeutic Class

Meglitinide Analogues.

 

Storage Conditions

Do not store at temperatures above 30°C. Keep out of the reach of youngsters and away from light.

 

Pharmaceutical Name

Alco Pharma Ltd.